Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

NCT03175224 is registered in ClinicalTrials.gov with Apollomics Inc. as lead sponsor.

NCT NCT03175224
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03175224 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Lead sponsor
Apollomics Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
September 27, 2017
Completion date
November 30, 2026
Enrollment
497 (estimated)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, brain tumor, colon cancer, egfr gene mutation, exon 14 skipping, gastric cancer, gastroesophageal junction adenocarcinoma, glioblastoma multiforme, hgf, lung cancer, met alteration, met amplification, met fusion, nsclc, pancreatic cancer, renal cancer, solid tumors, thyroid cancer